Decreased risk of ovarian cancer associated with rs9898876 sex hormone-binding globulin gene variant.
Haplotypes
Ovarian cancer
Polymorphism
Sex hormone-binding globulin
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
11
2021
accepted:
23
02
2022
revised:
16
02
2022
pubmed:
13
3
2022
medline:
14
7
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
Ovarian cancer (OC) is one of the most common gynecologic cancers,with significant morbidity and mortality. The risk of OC is influenced by hormone status, of which sex hormone-binding globulin (SHBG), which influences the serum availability of steroid sex hormones, is implicated in the pathogenesis and evolution of OC. The aim of this study is to evaluate the involvement of common SHBG gene variants in OC susceptibility and evolution. A case control study including 71 OC patients and 74 cancer-free controls, who were genotyped for rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP. Genotyping was done by the allelic discrimination method, using VIC- and FAM-labeled primers. The minor allele frequencies of rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP was comparable between OC cases and control women, implying no significant associations of the tested variants and overall OC risk. Taking homozygous wild-type genotype as reference (OR = 1.00), heterozygous rs9898876 (G/T), and minor allele-carrying genotypes [G/T + T/T] were associated with reduced risk of OC. While rs9898876 heterozygosity (G/T) was predictive of OC occurrence, no significant association of the remaining three tested SNPs was noted with altered risk of OC. Irrespective of FIGO staging, the four tested SHBG SNPs were not associated with the clinical progression of OC. In conclusion, SHBG rs9898876 is associated with a decreased risk of OC, and thus constitutes a potential diagnostic biomarker of OC.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OC) is one of the most common gynecologic cancers,with significant morbidity and mortality. The risk of OC is influenced by hormone status, of which sex hormone-binding globulin (SHBG), which influences the serum availability of steroid sex hormones, is implicated in the pathogenesis and evolution of OC. The aim of this study is to evaluate the involvement of common SHBG gene variants in OC susceptibility and evolution.
MATERIALS
METHODS
A case control study including 71 OC patients and 74 cancer-free controls, who were genotyped for rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP. Genotyping was done by the allelic discrimination method, using VIC- and FAM-labeled primers.
RESULTS
RESULTS
The minor allele frequencies of rs9898876, rs13894, rs1799941 and rs6257 SHBG SNP was comparable between OC cases and control women, implying no significant associations of the tested variants and overall OC risk. Taking homozygous wild-type genotype as reference (OR = 1.00), heterozygous rs9898876 (G/T), and minor allele-carrying genotypes [G/T + T/T] were associated with reduced risk of OC. While rs9898876 heterozygosity (G/T) was predictive of OC occurrence, no significant association of the remaining three tested SNPs was noted with altered risk of OC. Irrespective of FIGO staging, the four tested SHBG SNPs were not associated with the clinical progression of OC.
CONCLUSIONS
CONCLUSIONS
In conclusion, SHBG rs9898876 is associated with a decreased risk of OC, and thus constitutes a potential diagnostic biomarker of OC.
Identifiants
pubmed: 35277784
doi: 10.1007/s11033-022-07297-1
pii: 10.1007/s11033-022-07297-1
doi:
Substances chimiques
Sex Hormone-Binding Globulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4537-4544Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Torre LA, Traber B, Desantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics. CA: Cancer J Clinicians 68:284–296. https://doi.org/10.3322/caac.21456
doi: 10.3322/caac.21456
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
pubmed: 30207593
Devouassoux-Shisheboran M, Genestie C (2015) Pathobiology of ovarian carcinomas. Chin J Cancer 34:50–55. https://doi.org/10.5732/cjc.014.10273
doi: 10.5732/cjc.014.10273
pubmed: 25556618
pmcid: 4302089
Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW (2018) Major clinical research advances in gynecologic cancer in 2017. J Gynecol Oncol 29:e31. https://doi.org/10.3802/jgo.2018.29.e31
doi: 10.3802/jgo.2018.29.e31
pubmed: 29468855
pmcid: 5823987
Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ (2016) Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol 27 Suppl 1i4–i10. https://doi.org/10.1093/annonc/mdw083
Smith ER, Xu XX (2008) Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol 9:1108–1111. https://doi.org/10.1016/S1470-2045(08)70281-X
doi: 10.1016/S1470-2045(08)70281-X
pubmed: 19012860
pmcid: 2713057
Gharwan H, Bunch KP, Annunziata CM (2015) The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer 22:R339–R363. https://doi.org/10.1530/ERC-14-0550
doi: 10.1530/ERC-14-0550
pubmed: 26373571
Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmondson RJ (2012) Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124:142–147. https://doi.org/10.1016/j.ygyno.2011.09.004
doi: 10.1016/j.ygyno.2011.09.004
pubmed: 22001143
Kanabekova P, Al-Awadi AM, Bauyrzhanova Z, Tahtouh T, Sarray S, Almawi WY (2022) Genetic variation in progesterone receptor gene and ovarian cancer risk: A case control study. Gene 820:146288. https://doi.org/10.1016/j.gene.2022.146288
doi: 10.1016/j.gene.2022.146288
pubmed: 35143942
Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842. https://doi.org/10.1016/S0140-6736(14)61687-1
doi: 10.1016/S0140-6736(14)61687-1
pmcid: 4427760
Garcia-Closas M, Brinton LA, Lissowska J, Richesson D, Sherman ME, Szeszenia-Dabrowska N, Peplonska B, Welch R, Yeager M, Zatonski W, ChanockSJ (2007) Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. BMC Cancer 7:60. https://doi.org/10.1186/1471-2407-7-60
doi: 10.1186/1471-2407-7-60
pubmed: 17411440
pmcid: 1855931
Schock H, Surcel HM, Zeleniuch-Jacquotte A, Grankvist K, Lakso H, Fortner RT, Kaaks R, Pukkala E, Lehtinen M, Toniolo P, Lundin E (2014) Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer 21:831–844. https://doi.org/10.1530/ERC-14-0282
doi: 10.1530/ERC-14-0282
pubmed: 25270324
pmcid: 4282682
Hammond GL, Bocchinfuso WP (1996) Sex hormone-binding globulin: gene organization and structure/function analyses. Horm Res 45:197–201. https://doi.org/10.1159/000184787
doi: 10.1159/000184787
pubmed: 8964583
Hammond GL (2011) Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 85:431–441. https://doi.org/10.1095/biolreprod.111.092593
doi: 10.1095/biolreprod.111.092593
pubmed: 21613632
pmcid: 4480437
Abu-Hijleh TM, Gammoh E, Al-Busaidi AS, Malalla ZH, Madan S, Mahmood N, Almawi WY (2016) Common variants in the sex hormone-binding globulin (SHBG) gene influence SHBG levels in women with polycystic ovary syndrome. Ann Nutr Metab 68:66–74. https://doi.org/10.1159/000441570
doi: 10.1159/000441570
pubmed: 26600064
Hammond GL (2016) Plasma steroid-binding proteins:primary gatekeepers of steroid hormone action. J Endocrinol 230:R13–25. https://doi.org/10.1530/JOE-16-0070
doi: 10.1530/JOE-16-0070
pubmed: 27113851
pmcid: 5064763
Eriksson AL, Lorentzon M, Mellstrom D, Vandenput L, Swanson C, Andersson N, Hammond GL, Jakobsson J, Rane A et al (2006) SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 91:5029–5037. https://doi.org/10.1210/jc.2006-0679
doi: 10.1210/jc.2006-0679
pubmed: 16926255
Xita N, Tsatsoulis A (2010) Genetic variants of sex hormone-binding globulin and their biological consequences. Mol Cell Endocrinol 316:60–65. https://doi.org/10.1016/j.mce.2009.08.025
doi: 10.1016/j.mce.2009.08.025
pubmed: 19733622
Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, Folkerd E, Luben RN, Cox D et al (2008) Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:3490–3498. https://doi.org/10.1158/1055-9965.EPI-08-0734
doi: 10.1158/1055-9965.EPI-08-0734
pubmed: 19064566
pmcid: 2660245
Lee K, Sung J, Song YM (2015) Genetic and environmental influence on the association between testosterone, sex hormone-binding globulin and body composition in Korean men. Clin Endocrinol (Oxf) 83:236–245. https://doi.org/10.1111/cen.12722
doi: 10.1111/cen.12722
Turk A, Kopp P, Colangelo LA, Urbanek M, Wood K, Liu K, Skinner HG, Gapstur SM (2008) Associations of serum sex hormone binding globulin (SHBG) levels with SHBG gene polymorphisms in the CARDIA Male Hormone Study. Am J Epidemiol 167:412–418. https://doi.org/10.1093/aje/kwm332
doi: 10.1093/aje/kwm332
pubmed: 18056923
Quan L, Wang L, Wang J, Yuwen B, Zhu J (2019) Association between sex hormone binding globulin gene polymorphism and type 2 diabetes mellitus. Int J Clin Exp Pathol 12:3514–3520
pubmed: 31934198
pmcid: 6949838
Cousin P, Calemard-Michel L, Lejeune H, Raverot G, Yessaad N, Emptoz-Bonneton A, Morel Y, Pugeat M (2004) Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 89:917–924. https://doi.org/10.1210/jc.2002-021553
doi: 10.1210/jc.2002-021553
pubmed: 14764814
Haiman CA, Riley SE, Freedman ML, Setiawan VW, Conti DV, Le Marchand L (2005) Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab 90:2198–2204. https://doi.org/10.1210/jc.2004-1417
doi: 10.1210/jc.2004-1417
pubmed: 15634719
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ et al (2019) Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol 48:822–830. https://doi.org/10.1093/ije/dyz113
doi: 10.1093/ije/dyz113
pubmed: 31211375
pmcid: 6659359
Sarray S, Madan S, Saleh LR, Mahmoud N, Almawi WY (2015) Validity of adiponectin-to-leptin and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome. Fertil Steril 104:460–466. https://doi.org/10.1016/j.fertnstert.2015.05.007
doi: 10.1016/j.fertnstert.2015.05.007
pubmed: 26051098
Ángeles Martínez-García M, Gambineri A, Alpañés M, RaúlSanchón, Sanchon R, Pasquali R, Escobar-Morreale HF (2012) Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. Hum Reprod 27:3569–3576. https://doi.org/10.1093/humrep/des335
doi: 10.1093/humrep/des335
pubmed: 23001781
Wickham EP, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF (2011) Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 96:E719–E727. https://doi.org/10.1210/jc.2010-1842
doi: 10.1210/jc.2010-1842
pubmed: 21252242
pmcid: 3070246
Huang R, Ma Y, Holm R, Trope CG, Nesland JM, Suo Z (2013) Sex hormone-hinding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations. PLoS ONE 8:e83238. https://doi.org/10.1371/journal.pone.0083238
doi: 10.1371/journal.pone.0083238
pubmed: 24386165
pmcid: 3873286
Baker ME (2002) Albumin, steroid hormones and the origin of vertebrates. J Endocrinol 175:121–127. https://doi.org/10.1677/joe.0.1750121
doi: 10.1677/joe.0.1750121
pubmed: 12379496
Ose J, Fortner RT, Rinaldi S, Schock H, Overvad K, Tjonneland A, Hansen L, Dossus L, Fournier A et al (2015) Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 136:399–410. https://doi.org/10.1002/ijc.29000
doi: 10.1002/ijc.29000
pubmed: 24890047
Davis SR, Wahlin-Jacobsen S (2015) Testosterone in women-the clinical significance. Lancet Diabetes Endocrinol 3:980–992. https://doi.org/10.1016/S2213-8587(15)00284-3
doi: 10.1016/S2213-8587(15)00284-3
pubmed: 26358173
Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, Visvanathan K, Helzlsouer K, Buring JE et al (2017) Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res 77:3951–3960. https://doi.org/10.1158/0008-5472
doi: 10.1158/0008-5472
pubmed: 28381542
pmcid: 5512110
Paleari L, De Censi A (2018) Endocrine therapy in ovarian cancer: where do we stand? Curr Opin Obstet Gynecol 30:17–22. https://doi.org/10.1097/GCO.0000000000000423
doi: 10.1097/GCO.0000000000000423
pubmed: 29176513
Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H, Zhu X (2017) Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget 8:62400–62413. https://doi.org/10.18632/oncotarget.18253
doi: 10.18632/oncotarget.18253
pubmed: 28977954
pmcid: 5617514
Ahmed AB, Zidi S, Sghaier I, Ghazouani E, Mezlini A, Almawi W, Loueslati BY (2017) Common variants in IL-1RN, IL-1β and TNF-α and the risk of ovarian cancer: a case control study. Cent Eur J Immunol 42:150–155. https://doi.org/10.5114/ceji.2017.69356
doi: 10.5114/ceji.2017.69356
pubmed: 28860932
pmcid: 5573887
Ahmed AB, Zidi S, Almawi W, Ghazouani E, Mezlini A, Loueslati BY, Stayoussef M (2020) Single nucleotide polymorphism of transforming growth factor-beta1 and interleukin-6 as risk factors for ovarian cancer. Cent Eur J Immunol 45:267–275. https://doi.org/10.5114/ceji.2020.101242
doi: 10.5114/ceji.2020.101242
pubmed: 33437178
pmcid: 7790009
Stasenko M, Plegue M, Sciallis AP, McLean K (2015) Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status. Int J Gynecol Cancer 25:222–228. https://doi.org/10.1097/IGC.0000000000000334
doi: 10.1097/IGC.0000000000000334
pubmed: 25500503
Overbeek A, van den Berg MH, van Leeuwen FE, Kaspers GJ, Lambalk CB, van Dulmen-den Broeder E (2017) Chemotherapy-relatedlate adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer Treat Rev 53:10–24. https://doi.org/10.1016/j.ctrv.2016.11.006
doi: 10.1016/j.ctrv.2016.11.006
pubmed: 28056411
Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T, Geller MA, Langdon SP (2013) Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol 131:368–373. https://doi.org/10.1016/j.ygyno.2013.07.099
doi: 10.1016/j.ygyno.2013.07.099
pubmed: 23911795
Lorusso D, Di Stefano A, Fanfani F, Marini L, Adamo V, Scambia G (2006) Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17:188–194. https://doi.org/10.1093/annonc/mdj979
doi: 10.1093/annonc/mdj979
Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S et al (2013) Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 14:1009–1019. https://doi.org/10.1016/S1470-2045(13)70301-2
doi: 10.1016/S1470-2045(13)70301-2
pmcid: 4056766